Abstract
haemodynamic and renal excretory response to acute, priming dose ensured a serum activity of 200-600 c.p.m./ml systemic NO-inhibition with L-NMMA in healthy for [51Cr]EDTA and 800-1600 c.p.m./ml for [125I ]hippuran. sodium replete humans. In addition, we evaluated the Serum activity was kept stable by constant intravenous effects on several hormones of interest in the regulation infusion with an infusion pump ( Vial Medical, France). The of blood pressure and body fluid homeostasis.
employed model of tracer infusion and water loading gives stable values of RPF and GFR within the time frame of the present study [3] . Blood pressures were determined by a
Subjects and methods
semiautomatic device (Takeda, Japan) calibrated against a random zero sphygmomanometer (Hawksley, Lancing, UK ).
Subjects and study design Biochemical measurements
The study was approved by the local ethics committee and The Danish National Board of Health. Informed written Plasma levels of Ang II, Aldo, ANP, and BNP were measured consent was obtained from all participants. using radioimmunoassays as described in detail earlier Concerning CAND treatment the study was designed as a [12] [13] [14] [15] . Commercially available radioimmunoassay kits double-blind, placebo-controlled cross-over investigation. were used to measure plasma levels of renin (Nichols) and Fifteen healthy subjects (males/females, 8/7; age, 26±1 years) cGMP (Amersham). were studied on 2 study days with an interval of 14 days during pretreatment with either placebo or CAND in ran-Study drug domized order. On each study day the effects of L-NMMA was investigated using identical experimental procedures.
L-NMMA was obtained from Clinalfa AG, Switzerland. Before inclusion all subjects had a laboratory screening Candesartan cilexetil 8 mg and placebo tablets were supplied including plasma electrolytes, renal and liver function tests, by Astra, Denmark. blood counts, plasma cholesterol, plasma uric acid and urinary dip stick. In addition, a medical history and clinical
Calculations and statistics
examination including blood pressure measurements and ECG were performed. The subjects were to be in good health All clearance calculations are based on standard formulae without current medication or drug or alcohol abuse.
using the mean value of the two plasma levels before and after each clearance period. Values of GFR, RPF, lithium
L-NMMA treatment and experimental procedures
clearance and sodium clearance were normalized to a standard body surface area of 1.73 m2. Baseline results are reported Procedures on the two study days were identical. The subjects as the means of the results obtained from the initial two made 24-h urine collections the day before each experiment. clearance periods before L-NMMA intervention. WithinTablet lithium carbonate 300 mg was taken at 10.00 p.m. on group comparisons were performed by analysis of variance the evening before each experiment for the measurement of with repeated measures design and paired Students t tests lithium clearance. At 7.00 a.m. on the morning of the with Bonferoni correction as post-hoc tests. Comparisons experiment the subjects took 1 tablet containing either pla-between placebo and CAND treatment were performed using cebo (PLAC ) or candesartan cilexetil (CAND) 8 mg. At this paired Student's t test (baseline comparisons) or two-way point an oral water load of 200 ml tap water each 30 min repeated measures analysis of variance with time and CAND/ was commenced. Two indwelling catheters for blood sam-placebo treatment as factors. Treatment with CAND affected pling and administration of tracers and study drugs were baseline levels of some variables. We therefore used the placed in forearm veins, one in each arm. Urine was collected relative changes from baseline during L-NMMA treatment by voiding in the standing or sitting position and the subjects in the comparisons between placebo and CAND. Results are were otherwise kept in the supine position during the experi-given as means±SEM. All variables were normally or logment. At 08.30 hours a priming dose of [51Cr]EDTA and normally distributed. P<0.05 was considered the limit of [125I ]hippuran for the measurement of glomerular filtration significance. rate (GFR) and renal plasma flow (RPF ) was given, followed by sustained infusions of both. The study was divided in six clearance periods of 30 min. Two baseline periods were Results obtained from 10.00 hours to 11.00 hours. At 11.00 hours a bolus injection of L-NMMA (3 mg/kg) dissolved in 10 ml Baseline clinical and laboratory values of saline was given over 10 min. The study continued with four clearance periods to evaluate the effects of treatment. Twenty-four-hour urinary sodium excretions were simBlood samples were drawn each 30 min, i.e. before the first ilar on the study days (CAND 179±17 mmol/day vs clearance period and at the end of each period and were PLAC 167±15 mmol/day, P=NS ). Body weight, sysanalysed for tracers, osmolality, lithium, and electrolytes. In tolic and diastolic blood pressure and heart rate were addition analysis of the plasma levels of guanosine 3∞ 5∞-cyclic similar at baseline on the study days. Laboratory and RPF are depicted in Figure 2 . At baseline, RPF was significantly increased after treatment with CAND (RPF-cand: 547±28 ml/min vs RPF-plac: 482±25 ml/ min, P=0.0002) and FF decreased ( FF-cand 20.0±0.7% vs FF-plac 21.9±0.6%, P=0.0032).
L-NMMA induced a similar and sustained decrease in RPF during both placebo and CAND treatment with a maximum after 30 min (RPF-cand −20.6±1.6%, P<0.0001; RPF-plac −20.5±2.1%, P<0.0001). There was no difference in the relative response to L-NMMA treatment on the study days (P CAND VS PLAC =0.8027, Figure 2 ). L-NMMA induced a similar transient decrease in GFR after 30 min during both CAND and placebo treatment that quickly normalized towards baseline (GFR-cand −8.5±1.9%, P=0.0007; RPF-plac −8.5±2.1%, P=0.0013). There was no difference in the relative response to L-NMMA treatment on the study days (P CAND VS PLAC =0.8942, Figure 2 ). Filtration fraction increased significantly during both CAND and placebo treatment after L-NMMA as predicted from the sustained decrease in RPF and the relatively well preserved GFR. The changes in FF were evident throughout the experiment with a maximum after 30 min ( FF-cand +15.2±1.2%, P<0.0001; FF-plac +15.5±1.4%, P<0.0001). There was no difference in the relative changes in FF.
Urinary flow rate, absolute and fractional sodium excretion
Urinary flow rate ( V ), absolute urinary sodium excretion ( V*U Na ) and fractional sodium excretion (FE Na ) are shown in Table 2 . The relative changes in FE Na are Baseline values of V*U Na and FE Na were significantly CAND (+8.9±1.2%, P=0.0001) treatment with a increased on the CAND day ( Table 2) . Treatment with maximum 5-10 min after injection. The systemic MAP L-NMMA induced a similar decrease in FE Na during response to L-NMMA treatment tended to be lower placebo and CAND with a maximum after 30 min and and tended to normalize more quickly during CAN, lasting for 60 min ( FE Na cand −25.7±4.8%, P= but this difference failed to show statistical significance 0.0044; FE Na plac −21.5±3.5%, P=0.0001). The (P CAND VS PLAC =0.2205, Figure 1 ). relative L-NMMA induced changes in FE Na were Heart rate dropped significantly to a similar extent not significantly different (P CAND VS PLAC =0.4240, (P CAND VS PLAC =0.2326, Figure 1 ) on both study days Figure 3 ). after L-NMMA (PLAC −10.0±2.0%, P=0.0015;
The changes in V*U Na after L-NMMA were similar CAND −12.5±2.3%, P=0.0002).
to the changes in FE Na in both groups. In general, MAP and HR were normalized within 40-60 min after L-NMMA treatment on both study days.
Fractional lithium excretion
Fractional lithium excretion ( FE Li ) is shown in Table 2 .
Renal haemodynamics
At baseline, FE Li was slightly but not significantly increased during CAND treatment. Intervention with Absolute values of glomerular filtration rate (GFR), renal plasma flow (RPF ) and filtration fraction ( FF ) L-NMMA elicited a sustained decrease in FE Li on both study days with a maximum after 60 min ( FE Li are shown in Table 1 . The relative changes in GFR Table 1 . Glomerular filtration rate (GFR), renal plasma flow (RPF ), and filtration fraction (FF ) before and after acute L-NMMA treatment during pretreatment with candesartan (CAND) or placebo (PLAC ) 
Hormones
Results of the hormone measurements are shown in Table 3 . During CAND treatment there was a profound and significant increase in plasma levels of renin and Ang II at baseline (renin-cand+193.8±83.5% vs renin-plac, P=0.0199; Ang II-cand+274.5±147.0% vs Ang II-plac, P=0.0147). Plasma renin decreased significantly after L-NMMA only during CAND treatment (renin-cand −13.0±4.4%, P=0.0199). Plasma Ang II showed the same tendency but failed to show statistical significance. Plasma ANP values decreased slightly after L-NMMA during both CAND and placebo treatment. However, these changes were only significant during CAND treatment. Plasma levels of BNP and aldosterone were not affected by neither CAND nor L-NMMA treatment. Plasma levels and urinary excretion of cGMP decreased significantly and to a similar magnitude after L-NMMA on both study days.
Discussion
In the present study we have investigated the role of Ang II in mediating the systemic and renal response to acute NO synthesis inhibition in healthy subjects by pretreating 15 healthy subjects with the novel AT1-receptor antagonist candesartan cilexetil before intervention with L-NMMA in a double blind, placebo-controlled design. We found that AT-1 receptor blockade using CAND does not modify the acute effects of L-NMMA indicating no major role of Ang II in the NO-mediated effects on systemic and renal haemodynamics and sodium excretion in sodium replete humans. previously been shown in patients with hypertension [16 ] . L-NMMA treatment induced similar relative declines in RPF during placebo and CAND indicating that Ang II is probably not a main mediator of the cand −9.5±1.5%, P=0.0001; FE Li plac −12.7±2.5%, P=0.0001). There was no significant difference in the renal vasoconstriction during acute NO-inhibition.
Hence, in sodium-replete healthy subjects there is a relative L-NMMA-induced change in FE Li during PLAC and CAND treatment.
basal renal vasodilatory tone exerted by NO that is Table 2 . Urinary flow rate ( V ), absolute sodium excretion ( V*U Na ), fractional sodium excretion (FE Na ) and fractional lithium excretion (FE Li ) before and after acute L-NMMA treatment during pretreatment with candesartan (CAND) or placebo (PLAC ) levels after L-NMMA only during CAND treatment at a point where renin levels were greatly increased due to the blockade of Ang II mediated negative feedback effects on renin secretion. This transient decrease could be explained by the systemic pressor response. We did not see this decrease during placebo and this could be related to the fact that the renin assay probably detects small changes more sensitively during activation of RAS. Thus NO is probably not involved in the feedback activation of renin secretion seen during AT-1 receptor blockade. On the other hand we have earlier reported a more profound and sustained decrease in renin levels after a similar dose of L-NMMA during low sodium intake, i.e. with a comparable activation of renin secretion [17] . Hence in humans it may be suggested that NO is involved in low-sodium renin activation but not renin activation the role of Ang II in the response to L-NMMA in healthy humans. However, it was recently reported not caused by a selective opposal of the effects of Ang that losartan-another specific AT-1 receptor antagon-II. It is still possible that the increase in baseline RPF ist-was unable to prevent the renal effects of observed after CAND could be partly mediated by L-NAME in seven healthy subjects maintained on a NO. The absolute drop in RPF after L-NMMA was rather high sodium balance [11] . Thus, prevailing slightly but not significantly enhanced during CAND human evidence employing different AT-1 receptor (data not shown). However, the present study design antagonists and NO-inhibitors suggests that Ang II is was not suited to test this possibility.
not involved in the renal response to NO-inhibition in CAND treatment was accompanied by an increased the sodium repleted state. This is in agreement with a V*U Na and FE Na at baseline probably caused by an line of animal studies showing no effect of blockade inhibition of proximal tubular reabsorption. This was of the renin-angiotensin system on the renal response indicated by the increased-albeit not significantto NO inhibition using either ACE inhibitors or AT-1 baseline levels of FE Li during CAND treatment. These receptor antagonists [8, 10, 18, 19] . In contrast to this, results provide the first demonstration of a natriuretic a series of animal studies have shown complete or effect of candesartan cilexetil in humans. However, the partial abolition of the systemic and renal effects of relative response to L-NMMA remained intact with a NO inhibition, particularly during conditions of comparable decrease in V*U Na and FE Na and a increased RAS activity, such as anaesthesia and low comparable stimulation of proximal tubular sodium sodium balance [4, 5, 17, 20, 21] . Thus Ang II may play reabsorption during CAND and placebo. These a more significant role in the response to NO inhibition results suggest that the sodium-retaining effect of during conditions of increased RAS activity and the NO-inhibition are not due to an unopposed effect of conclusions of the present study should probably be Ang II.
We found a small transient drop in plasma renin confined to the sodium-replete state. Indeed, animal studies have indicated that NO exerts an important ant to our understanding of normal physiological interactions between NO and Ang II and may implicate protective antagonism during conditions of increased Ang II activity. During low NO activity the effects of that RAS activity is not a major determinant of hypertension induced by low NO activity. However, Ang II infusions are significantly enhanced [22] . Hence the degree of interaction between NO and Ang II is further studies are needed to clarify the interaction between NO and Ang II during increased Ang II probably more pronounced at the extremes of activity of each of these systems. activity in man. L-NMMA was used to block NO synthesis in this
